The Global Market for Bispecific Antibody Therapeutics Contract Manufacturing 2023-2030: Driven by Demand for Innovative Therapies and Promising Results Seen in Clinical Development
06 nov. 2023 09h04 HE
|
Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Therapeutics Contract Manufacturing Market 2023-2030" report has been added to ResearchAndMarkets.com's offering. The...
Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
06 nov. 2023 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on the potential use of investigational cancer immunotherapy...
New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented
26 oct. 2023 08h30 HE
|
Evaxion Biotech
Data from Evaxion’s two personalized cancer vaccine clinical trials to be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC)These new sets of clinical data further...
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
24 oct. 2023 04h00 HE
|
AKAMPION
Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress...
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
17 oct. 2023 04h00 HE
|
AKAMPION
- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors ...
ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development
19 sept. 2023 04h00 HE
|
AKAMPION
- Former Novartis Executive Director brings significant expertise in manufacturing, operations, and technical development Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA –...
Thermosome Establishes High-Profile Clinical Advisory Board
19 sept. 2023 04h00 HE
|
AKAMPION
Leveraging the transformative potential of TSL-based tumor targeting Supporting the progress of Thermosome's clinical candidate THE001 Munich, Germany – September 19, 2023 – Thermosome, a drug...
Cancer Immunotherapy Market Size to Reach USD 339.6 Billion by 2032 | CAGR: 14.5% | DataHorizzon Research
14 sept. 2023 08h20 HE
|
DataHorizzon Research
Fort Collins, Colorado, Sept. 14, 2023 (GLOBE NEWSWIRE) -- DataHorizzon Research Published a report titled, "Cancer Immunotherapy Market Size, Growth, Share, Statistics Report, By Type (Monoclonal...
Cancer Immunotherapy Market Set to Soar Past USD 309.67 Billion by 2030 | Skyquest Technology
17 août 2023 00h48 HE
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- According to SkyQuest's latest global research of the Cancer Immunotherapy market, increasing adoption of immune checkpoint inhibitors, development...
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
07 août 2023 07h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on investigational cancer immunotherapy PV-10 (rose bengal...